Open access
Oct 2026
Durable treatment response to Trastuzumab deruxtecan in two patients with recurrent grade III anaplastic ependymoma
Anaplastic ependymoma is a rare and aggressive central nervous system malignancy for which effective systemic treatment options are limited. Trastuzumab deruxtecan (T-DXd), an antibody–drug conjugate targeting human epidermal growth factor receptor 2 (HER2), has demonstrated intracranial activity in patients with HER2-...
D. Krex, I. Kerle, Arne Grey et al.
· Molecular and Cellular Pedia... · 1 citation